Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Immunology

Impact factor: 3.698

ISSN Print: 1040-8401
ISSN Online: 2162-6472

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v24.i5.30
14 pages

Role of the D Prostanoid Receptor 1 in the Modulation of Immune and Inflammatory Responses

Francois Trottein
Centre d'Immunologie et de Biologie Parasitaire, Institut National de la Sante et de la Recherche Medicale U547, Institut Pasteur de Lille, 59019 Lille cedex, France
Christelle Faveeuw
Centre d'Immunologie et de Biologie Parasitaire, Institut National de la Sante et de la Recherche Medicale U547, Institut Pasteur de Lille, 59019 Lille cedex, France
Philippe Gosset
Institut National de la Sante et dela Recherche Medicale U416, Institut Pasteur de Lille, 59019, Lille cedex, France
Veronique Angeli
Centre d’Immunologie et de Biologie Parasitaire,Institut National de la Sante et de la Recherche Medicale U547,Institut Pasteur de Lille,59019 Lille cedex, France; Department of Gene and Cell Medicine,Mount Sinai School of Medicine,New York, NY 10029

ABSTRACT

Prostaglandins (PGs) are potent eicosanoid lipid mediators derived from phospholipase-released arachidonic acid, which are involved in numerous homeostatic biological functions and inflammation. They are generated by the sequential action of cyclooxygenase isozymes and cell-specific PG synthases. Along with their role in inflammatory responses, recent accumulating evidence strongly suggests that PGs, including PGD2, are part of a complex regulatory network that modulates the immune system. PGD2 is the major prostanoid secreted by activated mast cells and has long been implicated in allergic diseases. The aim of this review is to discuss our current understanding of the mode of action of PGD2 during Th2-mediated inflammation. We also discuss recent findings, which suggest that PGD2 exerts important effects on both immune and inflammatory responses by targeting the D prostanoid receptor 1 on dendritic cells, the most potent antigen-presenting cells.